Latest News

Updated results from Phase 3 trial of IVIG for Alzheimer's disease

Neurologists have reported new findings from the Phase 3 clinical trial of IVIG (intravenous immunoglobulin) in mild to moderate Alzheimer's disease. While the primary study outcomes were negative, observations from the subgroup analyses include whether there may be a dose-dependent reduction of beta amyloid in the blood and brain of IVIG-treated Alzheimer's patients who have the ApoE4 genotype.
View full story

Post your comment.

Name:
Email:
Rating:
Comment:
Verification
 

  • Brain formation pattern shows why early trauma may leave no clues

  • Structure of brain plaques in Huntington's disease described

  • More effective speech therapy approach for children with Down Syndrome

  • Immune therapy for brain tumors: A new promising avenue

  • Parental depression associated with worse school performance by children

  • Investigating potential fetal exposure to antidepressants

  • Difficult grammar affects music experience

  • Parkinson's disease diagnosis may be preceded by increased risk of injury-causing falls

  • Pills for anxiety, sleep problems not linked to increased dementia risk

  • Online therapy can help those affected by body dysmorphic disorder

  •